To investigate whether CTCs enumeration may serve as a predictor of therapeutic response in advanced GC patients using the both CSV and EpCAM methods, 66 patients with advanced-stage disease were categorized into responsive/stable disease (SD) and non-responsive/progressive disease (PD) groups, based on the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 during blood sample collection. Here, EPCAM is linked to gastric cancer.